Table 1.
Baseline demographics and disease characteristics
| Characteristics | SB4 50 mg (n = 299) | ETN 50 mg (n = 297) | Total (n = 596) |
|---|---|---|---|
| Age, years | 52.1 (11.72) | 51.6 (11.63) | 51.8 (11.67) |
| Age group, n (%) | |||
| <65 years | 253 (84.6) | 262 (88.2) | 515 (86.4) |
| ≥65 years | 46 (15.4) | 35 (11.8) | 81 (13.6) |
| Gender, n (%) | |||
| Male | 50 (16.7) | 44 (14.8) | 94 (15.8) |
| Female | 249 (83.3) | 253 (85.2) | 502 (84.2) |
| Race, n (%) | |||
| White | 279 (93.3) | 273 (91.9) | 552 (92.6) |
| American Indian or Alaskan Native | 5 (1.7) | 7 (2.4) | 12 (2.0) |
| Asian | 11 (3.7) | 13 (4.4) | 24 (4.0) |
| Other | 4 (1.3) | 4 (1.3) | 8 (1.3) |
| Weight, kg | 72.5 (15.93) | 71.0 (14.63) | 71.8 (15.30) |
| Height, cm | 164.4 (8.78) | 164.4 (8.55) | 164.4 (8.66) |
| BMI, kg/m2 | 26.8 (5.51) | 26.3 (5.30) | 26.6 (5.41) |
| Disease duration, years | 6.0 (4.20) | 6.2 (4.41) | 6.1 (4.30) |
| Duration of MTX use, months | 48.2 (39.89) | 47.1 (40.73) | 47.7 (40.28) |
| MTX dose, mg/week | 15.6 (4.52) | 15.5 (4.60) | 15.5 (4.56) |
| CRP, mg/dl | 1.5 (2.00) | 1.3 (1.60) | 1.4 (1.81) |
| ESR, mm/h | 46.5 (22.10) | 46.4 (22.62) | 46.5 (22.34) |
| RF positive, n (%) | 237 (79.3) | 231 (77.8) | 468 (78.5) |
| Swollen joint count (0–66) | 15.4 (7.48) | 15.0 (7.30) | 15.2 (7.39) |
| Tender joint count (0–68) | 23.5 (11.90) | 23.6 (12.64) | 23.5 (12.26) |
| HAQ-DI (0–3) | 1.49 (0.553) | 1.51 (0.560) | 1.50 (0.556) |
| Physician global assessment VAS (0–100) | 62.2 (15.09) | 63.2 (14.76) | 62.7 (14.92) |
| Patient global assessment VAS (0–100) | 61.7 (18.97) | 63.0 (17.70) | 62.4 (18.35) |
| Patient pain assessment VAS (0–100) | 61.8 (20.22) | 62.3 (19.22) | 62.1 (19.71) |
| DAS28-ESR | 6.48 (0.906) | 6.46 (0.885) | 6.47 (0.895) |
| Simplified disease activity index | 39.8 (12.76) | 39.4 (11.81) | 39.6 (12.29) |
| Clinical disease activity index | 38.4 (12.24) | 38.1 (11.57) | 38.2 (11.90) |
| Joint space narrowing scorea | 19.2 (28.83) | 18.4 (26.48) | 18.8 (27.71) |
| Joint erosion scorea | 24.0 (39.63) | 20.5 (28.32) | 22.4 (34.71) |
| Modified total Sharp scorea | 43.3 (67.08) | 38.9 (53.26) | 41.2 (60.86) |
Values are mean (s.d.) unless indicated otherwise.
a
Based on patients with available radiographic data.
ETN: reference etanercept; VAS: visual analogue scale.